Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decision

Reports

2

Domains carrying it

2

First reported

13 August 2026

Latest report

13 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 13 August 2026Zealand sells rights to Takeda's blood cancer drug for $100Mfiercebiotech.com
2. 13 August 2026Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decisionallsci.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder14 reports · 12 domains · 1 September 2026
• BioMarin lands 20% Yuviwel royalty in Ascendis patent settlement2 reports · 2 domains · 1 September 2026
• US FDA approves Takeda, Protagonist's drug for rare blood cancer3 reports · 3 domains · 1 September 2026
• Protagonist Therapeutics (PTGX) As MIMRYLO Approval Reshapes The Valuation Debate3 reports · 1 domains · 30 August 2026
• Revolution Medicines drops despite first FDA nod (RVMD:NASDAQ)2 reports · 2 domains · 1 September 2026
• U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...12 reports · 12 domains · 17 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decisionallsci.com · 13 August 2026
• Zealand sells rights to Takeda's blood cancer drug for $100Mfiercebiotech.com · 13 August 2026